Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Low Dose Cytarabine in High-risk MDS
NCT00411905Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Jun 2006
- Primary completion
- Jul 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Started Jun 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00411905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00411905.